ATE428719T1 - Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors - Google Patents

Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors

Info

Publication number
ATE428719T1
ATE428719T1 AT00948923T AT00948923T ATE428719T1 AT E428719 T1 ATE428719 T1 AT E428719T1 AT 00948923 T AT00948923 T AT 00948923T AT 00948923 T AT00948923 T AT 00948923T AT E428719 T1 ATE428719 T1 AT E428719T1
Authority
AT
Austria
Prior art keywords
nucleic acid
hgf
acid ligands
factor
growth factor
Prior art date
Application number
AT00948923T
Other languages
English (en)
Inventor
Judy Ruckman
Larry Gold
Andrew Stephens
Nebojsa Janjic
Ross Rabin
Michael Lochrie
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/364,539 external-priority patent/US6344321B1/en
Priority claimed from US09/364,543 external-priority patent/US6331394B1/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE428719T1 publication Critical patent/ATE428719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00948923T 1999-07-29 2000-07-24 Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors ATE428719T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/364,539 US6344321B1 (en) 1990-06-11 1999-07-29 Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US09/364,543 US6331394B1 (en) 1991-06-10 1999-07-29 Nucleic acid ligands to integrins
PCT/US2000/020139 WO2001009159A1 (en) 1990-06-11 2000-07-24 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins

Publications (1)

Publication Number Publication Date
ATE428719T1 true ATE428719T1 (de) 2009-05-15

Family

ID=40577369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948923T ATE428719T1 (de) 1999-07-29 2000-07-24 Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors

Country Status (3)

Country Link
US (3) US20030049644A1 (de)
AT (1) ATE428719T1 (de)
DE (1) DE60042021D1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389710B2 (en) * 2004-02-27 2013-03-05 Operational Technologies Corporation Therapeutic nucleic acid-3′-conjugates
FR2867784B1 (fr) * 2004-03-17 2006-06-09 Commissariat Energie Atomique Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications
WO2007004748A1 (ja) * 2005-07-05 2007-01-11 Ribomic Inc. 免疫グロブリンｇに結合する核酸とその利用法
WO2007119447A1 (ja) * 2006-03-20 2007-10-25 Seikagaku Corporation 関節リウマチの処置剤
JP4698559B2 (ja) * 2006-11-24 2011-06-08 Ｎｅｃソフト株式会社 ウサギ由来のＩｇＧ抗体に結合性を有する核酸分子
HUE029445T2 (en) 2006-12-19 2017-02-28 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
US20100055099A1 (en) * 2008-08-29 2010-03-04 Ellen Filvaroff Diagnostics and Treatments for VEGF-Independent Tumors
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
US8236570B2 (en) * 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) * 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US20140148503A1 (en) * 2011-07-20 2014-05-29 University Of Iowa Research Foundation Nucleic acid aptamers
AR087918A1 (es) 2011-09-19 2014-04-23 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP3808778A1 (de) 2014-04-18 2021-04-21 Acceleron Pharma Inc. Verfahren zur erhöhung der erythrozytenkonzentration und behandlung der sichelzellenanämie
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
MA41920B1 (fr) 2015-04-06 2021-05-31 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
AU2016301380B2 (en) 2015-08-04 2021-07-01 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
EP3370754A4 (de) 2015-11-04 2019-10-23 Acceleron Pharma Inc. Verfahren zur erhöhung der erythrozytenkonzentration und behandlung von ineffizienter erythropoiese
JP7072507B2 (ja) 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
EP3928784A1 (de) 2016-07-15 2021-12-29 Acceleron Pharma Inc. Zusammensetzungen enthaltend actriia-polypeptide zur verwendung bei der behandlung von pulmonaler hypertonie
SI3490582T1 (sl) 2016-07-27 2024-09-30 Acceleron Pharma Inc. Sestavki za uporabo proti zdravljenju mielofibroze
AU2017340504A1 (en) 2016-10-05 2019-04-11 Acceleron Pharma, Inc. Compositions and method for treating kidney disease
US12364736B2 (en) 2018-02-09 2025-07-22 Acceleron Pharma Inc. Methods for treating heterotopic ossification

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3590766T (de) * 1985-03-30 1987-04-23
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5731424A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6270472B1 (en) * 1998-12-29 2001-08-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Apparatus and a method for automatically introducing implants into soft tissue with adjustable spacing
US20020165188A1 (en) * 1999-10-14 2002-11-07 Meenhard Herlyn Methods for inhibition of tumorigenic properties of melanoma cells

Also Published As

Publication number Publication date
US20030049644A1 (en) 2003-03-13
DE60042021D1 (de) 2009-05-28
US20060148748A1 (en) 2006-07-06
US20090075922A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
ATE428719T1 (de) Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
Ehrlich et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
Tassone et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma
CR6392A (es) Moduladores de ccr5
Zalachoras et al. Opposite effects of stress on effortful motivation in high and low anxiety are mediated by CRHR1 in the VTA
Melamed et al. A functional B cell receptor transgene allows efficient IL-7-independent maturation of B cell precursors
YU40701A (sh) Piperidini kao modulatori ccr5
ATE314116T1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
Cook et al. The role of plasma granulocyte colony stimulating factor and bone marrow dysfunction after severe trauma
DE60236206D1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
DE69931930D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
BR0010702A (pt) Novas quinonas como terapias de doenças
AR036741A1 (es) Combinaciones para el tratamiento de los trastornos inmunoinflamatorios
Li et al. Ultrasound irradiation combined with hepatocyte growth factor accelerate the hepatic differentiation of human bone marrow mesenchymal stem cells
PA8429901A1 (es) Compuestos antipicornavirales y metodos para su uso y preparacion
TR200402529T4 (tr) Yeni Fenalliloksi fenil türevleri.
DE60128368D1 (de) Diagnose und behandlung von prostatakrebs
DE69634499D1 (de) Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
Anderson et al. CCR6+ γδ T cells home to skin wounds and restore normal wound healing in CCR6-deficient mice
DE60238945D1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
Garn et al. Phenotypical and functional characterization of alveolar macrophage subpopulations in the lungs of NO2-exposed rats
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
GB9610281D0 (en) Diagnostic method and apparatus
Duque et al. EGCG and Taxifolin Modulate Secretory Activity and Expression of Dentinogenesis Markers in Odontoblast‐Like Cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties